Skip to main content
Print Save

Dupilumab Disease Interactions

There are 3 disease interactions with dupilumab.

Major

Interleukin inhibitors (applies to dupilumab) immunization

Major Potential Hazard, Moderate plausibility. Applicable conditions: Vaccination

Patients requiring non-live vaccination during a course of therapy with interleukin inhibitors may not be protected from the vaccine as the immune response might not be sufficient to prevent the disease. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating therapy with these agents. Patients treated with interleukin inhibitors should not receive live vaccines due to potentially increased risk of infections. Caution is advised when administering live vaccines to household contacts of patients receiving interleukin inhibitors because of the potential risk for shedding from the household contact and transmission to patient.

References

  1. "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals (2009):
  2. "Product Information. Actemra (tocilizumab)." Genentech (2010):
  3. "Product Information. Sylvant (siltuximab)." Janssen Biotech, Inc. (2014):
  4. "Product Information. Cosentyx (secukinumab)." Novartis Pharmaceuticals (2015):
  5. "Product Information. Nucala (mepolizumab)." GlaxoSmithKline (2015):
  6. "Product Information. Dupixent (dupilumab)." sanofi-aventis (2017):
  7. "Product Information. Kevzara (sarilumab)." sanofi-aventis (2017):
  8. "Product Information. Tremfya (guselkumab)." Janssen Biotech, Inc. (2017):
View all 8 references
Moderate

Dupilumab (applies to dupilumab) helminth infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Patients with preexisting-existing helminth infections should be treated prior to therapy with dupilumab. It is recommended to discontinue treatment with dupilumab if patients become infected while on treatment and if they are not responding to treatment. Discontinue treatment with dupilumab until the infection resolves.

References

  1. "Product Information. Dupixent (dupilumab)." sanofi-aventis (2017):
Moderate

Dupilumab (applies to dupilumab) visual defects

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Conjunctivitis and keratitis may occur while on treatment with dupilumab. Care should be exercised when using this agent in patients with visual defects. Patients should be closely monitored for new onset or worsening eye symptoms.

References

  1. "Product Information. Dupixent (dupilumab)." sanofi-aventis (2017):

Dupilumab drug interactions

There are 69 drug interactions with dupilumab.

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer